Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Adrian OoLaboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Angel BorgeDepartment of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts, USA.ORCID 0000-0002-5667-4894
Regina Ching Hua LeeLaboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Cyrill Kafi SalimLaboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Wenyu WangDepartment of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts, USA.
Michael RiccaDepartment of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts, USA.ORCID 0000-0001-8531-3863
Deborah Yuhui FongLaboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Sylvie AlonsoInfectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Lauren E BrownDepartment of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts, USA.ORCID 0000-0001-9489-484X
John A PorcoDepartment of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts, USA.ORCID 0000-0002-2991-5680
Justin Jang Hann ChuLaboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-1673-6819
Funding
Chemical Synthesis of Complex Natural Products for Translational ScienceR35GM118173 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI JOHN A. PORCO · 2016 to 2026
$8.2M
BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational DiscoveryU01TR002625 · NCATS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI PORCO, JOHN A. · 2020 to 2023
$2.7M
Novel Aglains as Therapeutic Agents for Mosquito-borne ArbovirusesR01AI189900 · NIAID · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Justin Jang Hann Chu, JOHN A. PORCO · 2025 to 2026
$1.6M
Acquisition of a Single Crystal X-ray Diffraction System for Macromolecular and Small Molecule CrytsallographyS10OD028585 · OD · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI ALLEN, KAREN N. · 2021 to 2021
$561k
NCATS NIH HHS U01 TR002625NIAID NIH HHS R01 AI189900NIGMS NIH HHS R35 GM118173NIH HHS S10 OD028585This work was supported by Singapore National Research Foundation Competitive Research Programme (NRF-CRP21-2018-0004) (SA & JJHC), Singapore Ministry of Education (MOE) Academic Research Fund (AcRF) Tier 2 (MOE-T2EP30221-0005) (JJHC), and NIH grants R35GM118173 and U01TR002625 (JAP, Jr.). We thank the National Science Foundation for support of NMR (CHE-0619339) and MS (CHE-0443618) facilities at BU, and the NIH (S10OD028585) for support of the single-crystal XRD system.
6 · The paper itself
Abstract
The lack of effective antiviral treatments for enteroviruses, including human enterovirus A71 (EV-A71), have resulted in an immense global healthcare burden associated with hand-foot-and-mouth disease (HFMD). Rocaglates and aglains belong to a family of compounds produced by Aglaia genus plants. Since the initial discovery of rocaglates in 1982, various rocaglates and aglains have been synthesized and extensively studied mainly as anticancer agents. Here, we report the discovery of a novel aglain derivative as a potential EV-A71 inhibitor. From an immunofluorescence-based phenotypic screen of a library of 296 rocaglate and aglain derivatives, we identified a lead aglain which effectively suppressed EV-A71 replication by 2.3 log fold at a non-cytotoxic concentration, with a host cell CC
Indexed as
Antiviral AgentsBenzofuransEnterovirus A, HumanHand, Foot and Mouth DiseaseAnimalsCell LineDrug DiscoveryDrug Evaluation, PreclinicalHumansVirus ReplicationAntiviral AgentsBenzofuransaglainantiviral agentsenterovirushand, foot, and mouth diseasenatural productspentafluorophenyl
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
In Vitro Discovery of a Therapeutic Lead for HFMD From a Library Screen of Rocaglates/Aglains. · full record | OpenQuestion